Close Menu
Home » Qiagen JAK2 Test Gets FDA Clearance for Additional Blood Cancer Types

Qiagen JAK2 Test Gets FDA Clearance for Additional Blood Cancer Types

Jan 23, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Qiagen said after the close of the market on Tuesday that it received US Food and Drug Administration clearance for its Ipsogen JAK2 RGQ PCR Kit for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Ah, That's What It Is

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

Billions Requested

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

What to Do

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

PNAS Papers on Heart Transplant Rejection, CAR-T Profiling, Thiopurine Toxicity Variants

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. Co-Diagnostics SARS-CoV-2 Assay Garners CE Mark

  2. Asuragen Fragile X Diagnostic Test Gets FDA Authorization

  3. Luminex Submits Verigene II Respiratory Assay for FDA Clearance

  4. FDA Releases List of Evidence-Based PGx Variants

  5. Streck Antibiotic Resistance Kits Receive CE Mark

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.